U.S. Administration’s Focus on Trade Practices
The current administration is set on addressing the issues caused by foreign governments that have negatively impacted American workers and businesses over the years. This was clearly articulated by the president during a recent speech at the World Economic Forum, where he highlighted the challenges faced by American entities.
Experts have largely concentrated on the administration’s notable response: the tariffs imposed last year. These tariffs have been a recurring topic for the president and his advisors, who argue they’re a means to revive supply chains and enhance domestic industry, which subsequently favors American businesses and employment opportunities.
But there’s more happening behind the scenes. The administration is discreetly urging foreign nations to strengthen protections for U.S. companies regarding intellectual property. This move aims to prevent the erosion of foreign intellectual property rights, which, in turn, supports American innovation.
The U.S. economy increasingly relies on businesses that invest significant resources into the development of new technologies. Strong intellectual property laws are critical for safeguarding these investments, ensuring that all Americans can benefit from the resulting economic progress and advancements. In fact, industries focused on intellectual property account for nearly half of the U.S. GDP and over 62 million jobs.
This is why, over time, the administration’s subtle push to fortify intellectual property protections might be more advantageous to American businesses and consumers than the much-discussed tariffs.
Foreign governments’ unfair trade practices, particularly affect the pharmaceutical sector. Even though American firms lead in drug development globally, many foreign nations undervalue these products through various means like price controls and forced rebates. This diminishes the profit potential for American innovations, putting undue financial pressure on U.S. patients.
For instance, the European Union recently made significant changes to its Generic Medicines Act, which shortens the exclusive marketing duration of new drugs and imposes stringent regulatory challenges. Furthermore, the EU is contemplating regulations that would enable governments to compel companies to share patented technologies.
Meanwhile, Mexico has not adhered to crucial intellectual property commitments under the USMCA trade agreement initiated during the first Trump term. The country permits early product launches by generic manufacturers without sufficient systems in place to validate existing patents. This leaves U.S. biotechnology firms inadequately informed or unable to safeguard their patent rights effectively.
Thus, it is vital for the U.S. to consider adding Mexico to the priority watch list in the Special 301 Report and to maintain pressure for compliance with USMCA commitments.
The administration has already begun applying pressure in various ways regarding partners who fall short. A recent agreement with the UK aims to cap revenue from biotech companies in exchange for tariff exemptions on UK-produced medicines, showing a model of negotiation that officials hope to replicate with other nations.
Additionally, there are initiatives to block imports of products, including pharmaceuticals and tech components, if they violate U.S. intellectual property rights.
Notably, last summer, the Department of Justice and the Patent and Trademark Office intervened in a case involving Samsung and Radian Memory Systems. The startup alleged that Samsung appropriated its patented technology. Both agencies indicated that patent violations could severely hinder American startups and suggested that courts impose injunctions to guard against such acts.
In late February, further legal actions were taken to support this position, reaffirming the right to seek injunctions in patent disputes.
There’s certainly more that could be done. The administration might encourage Congress to pass the bipartisan RESTORE Patent Rights Act, which would simplify the process for courts to issue injunctions against patent violations, thereby granting U.S. companies a stronger stance against foreign infringements.
The U.S. Trade Representative’s office could also contemplate placing the European Union on its Special 301 Watch List, spotlighting trading partners that habitually violate U.S. companies’ intellectual property rights. This could motivate the EU to revisit its current protocols. Similarly, there’s potential to use the upcoming review of the USMCA to insist that Mexico fulfills its obligations.
The tariffs may command more attention in the media. However, the quieter governmental efforts to bolster and uphold intellectual property rights for American companies could play a significant role in redefining global trade, making it more favorable for U.S. innovators, workers, and investors.
